
The Siesta Group is a pioneering company specializing in measuring, analyzing, and interpreting bio-signals such as EEG, polysomnography (PSG), and actigraphy data for CNS clinical trials. They provide end-to-end biomarker solutions including AI-powered sleep staging, biomarker identification, and advanced data visualization optimized for high-dimensional data. Their services support pharmaceutical and biotechnology companies globally, with over 20 years of experience, 100+ clinical trials supported, and more than 100,000 PSG and EEG recordings analyzed. The company is known for its proprietary software innovations like Somnolyzer 24x7, a benchmark tool for computer-assisted sleep scoring, and the Hypoxic Burden Platform for sleep apnea analysis. They maintain high compliance standards (CH-GCP, GDPR, 21CFR P11, AASM certified) and collaborate with a large international academic network, making them a key player in neurology drug development and CNS biomarker research.

The Siesta Group is a pioneering company specializing in measuring, analyzing, and interpreting bio-signals such as EEG, polysomnography (PSG), and actigraphy data for CNS clinical trials. They provide end-to-end biomarker solutions including AI-powered sleep staging, biomarker identification, and advanced data visualization optimized for high-dimensional data. Their services support pharmaceutical and biotechnology companies globally, with over 20 years of experience, 100+ clinical trials supported, and more than 100,000 PSG and EEG recordings analyzed. The company is known for its proprietary software innovations like Somnolyzer 24x7, a benchmark tool for computer-assisted sleep scoring, and the Hypoxic Burden Platform for sleep apnea analysis. They maintain high compliance standards (CH-GCP, GDPR, 21CFR P11, AASM certified) and collaborate with a large international academic network, making them a key player in neurology drug development and CNS biomarker research.
Specialty: CRO for sleep, EEG and CNS biomarkers (PSG, pharmaco‑EEG, actigraphy)
Founded: 2002 (Vienna headquarters)
Scale: ~19 employees; 100+ clinical trials supported; 100,000+ PSG/EEG recordings analyzed
Proprietary tools: Somnolyzer 24x7 (computer‑assisted sleep scoring); Hypoxic Burden Platform
Compliance: ICH‑GCP/CH‑GCP, GDPR, 21CFR P11, AASM certified
Measurement, scoring and biomarker extraction from polysomnography, EEG (pharmaco‑EEG, ERP) and actigraphy for CNS clinical trials.
2002
Biotechnology
Investors listed for the company include Gamma Capital Partners and Univenture; specific round amount not disclosed.
“Gamma Capital Partners; Univenture”